See more : Wiener Privatbank SE (WPB.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Intercept Pharmaceuticals, Inc. (ICPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intercept Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CIT Group Inc. (CIT) Income Statement Analysis – Financial Results
- Johnson & Johnson (JNJ.DE) Income Statement Analysis – Financial Results
- Sobal Corporation (2186.T) Income Statement Analysis – Financial Results
- Calbee, Inc. (CLBEY) Income Statement Analysis – Financial Results
- Foresight Acquisition Corp. (FOREW) Income Statement Analysis – Financial Results
Intercept Pharmaceuticals, Inc. (ICPT)
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 285.71M | 363.47M | 312.69M | 252.00M | 179.80M | 130.96M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Cost of Revenue | 984.00K | 3.10M | 5.32M | 4.21M | 2.52M | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 284.73M | 360.37M | 307.37M | 247.79M | 177.29M | 129.59M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Gross Profit Ratio | 99.66% | 99.15% | 98.30% | 98.33% | 98.60% | 98.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 176.64M | 185.27M | 191.49M | 242.80M | 207.30M | 191.50M | 153.89M | 128.19M | 80.31M | 27.94M | 16.18M | 11.43M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 255.47M | 0.00 | 0.00 | 103.75M | 34.60M | 13.13M | 4.85M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -161.00 | 331.87K | 0.00 | 0.00 |
| SG&A | 176.30M | 230.86M | 332.49M | 317.42M | 255.47M | 273.70M | 273.60M | 103.75M | 34.60M | 13.13M | 5.18M | 4.21M | 3.64M |
| Other Expenses | 6.52M | 2.16M | 4.41M | 8.89M | 6.77M | 4.52M | 3.90M | 2.73M | 776.00K | 100.38K | -104.00K | 0.00 | 104.55K |
| Operating Expenses | 352.94M | 416.13M | 523.98M | 560.22M | 462.78M | 465.20M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Cost & Expenses | 353.93M | 419.23M | 529.30M | 564.43M | 465.29M | 466.57M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Interest Income | 15.51M | 47.77M | 39.80M | 33.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.45K | 0.00 |
| Interest Expense | 21.39M | 54.42M | 48.05M | 41.14M | 30.52M | 29.27M | 14.20M | 0.00 | 0.00 | 0.00 | 0.00 | 13.48K | 0.00 |
| Depreciation & Amortization | 6.52M | 2.16M | 4.41M | 8.89M | 4.58M | 4.60M | 3.83M | 1.69M | 442.80K | 105.68K | 201.32K | 410.60K | 479.50K |
| EBITDA | -61.70M | -53.60M | -212.20M | -303.54M | -278.72M | -331.10M | -398.63M | -226.43M | 57.66M | -10.90M | 5.71M | -14.46M | -16.06M |
| EBITDA Ratio | -21.59% | -14.75% | -67.86% | -120.45% | -155.01% | -252.83% | -1,597.67% | -8,139.07% | 3,310.10% | -672.47% | 233.52% | -801.31% | 0.00% |
| Operating Income | -68.22M | -55.76M | -216.61M | -312.43M | -285.49M | -335.61M | -402.54M | -229.16M | -113.17M | -39.45M | -18.91M | -14.88M | -16.35M |
| Operating Income Ratio | -23.88% | -15.34% | -69.27% | -123.98% | -158.78% | -256.28% | -1,613.31% | -8,237.10% | -6,496.56% | -2,432.85% | -773.25% | -824.06% | 0.00% |
| Total Other Income/Expenses | -106.64M | -35.67M | -43.64M | -32.25M | -23.75M | -24.76M | -10.29M | 2.73M | -170.06M | -28.34M | -24.73M | 0.00 | 1.27M |
| Income Before Tax | -174.86M | -91.43M | -274.88M | -344.68M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -13.83M | -15.09M |
| Income Before Tax Ratio | -61.20% | -25.15% | -87.91% | -136.78% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -766.17% | 0.00% |
| Income Tax Expense | -290.03M | 53.60M | 49.35M | 46.37M | 6.77M | 29.19M | 14.27M | 1.04M | 170.39M | 28.44M | 24.42M | -1.09M | -672.48K |
| Net Income | 115.17M | -145.02M | -324.23M | -391.05M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -12.74M | -15.09M |
| Net Income Ratio | 40.31% | -39.90% | -103.69% | -155.18% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -705.64% | 0.00% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| EPS Diluted | 3.40 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| Weighted Avg Shares Out | 33.82M | 31.86M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
| Weighted Avg Shares Out (Dil) | 33.84M | 31.89M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
Why Intercept Pharmaceuticals Stock Plunged Today
Intercept Pharmaceuticals reported 2023 Q1 earnings today. The company missed Wall Street's revenue estimate for the three-month period by approximately $4.7 million.
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Call Transcript
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Call Transcript.
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
Intercept Pharmaceuticals (ICPT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.58 per share a year ago.
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
Ocaliva® net sales of $68.0 million, representing 15% growth over the prior year quarter Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting set for May 19, 2023, to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH; PDUFA...
Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
Seven abstracts in primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) accepted at EASL 2023
Intercept (ICPT) Moves 15.0% Higher: Will This Strength Last?
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015...
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
Source: https://incomestatements.info
Category: Stock Reports